Bausch + Lomb Announces U.S. Launch of StableVisc Cohesive Ophthalmic Viscosurgical Device and TotalVisc Viscoelastic System

Bausch + Lomb announced the US launch of StableVisc cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc Viscoelastic System. StableVisc and TotalVisc provide eye surgeons with new options for dual-action protection during cataract surgery.

StableVisc, a cohesive OVD, is designed to help maintain space in the anterior chamber of the eye to allow surgeons to extract and replace the clouded natural lens. TotalVisc Viscoelastic System includes both StableVisc and ClearVisc, a dispersive OVD, and protects ocular tissue during the surgical procedure. ClearVisc was approved by the FDA in 2021.

StableVisc and ClearVisc both contain sodium hyaluronate and sorbitol, a unique chemical agent that has been shown to create a strong physical barrier and deliver increased free radical scavenging capabilities compared to other OVDs tested in a laboratory study.[2,3] TotalVisc OVD provides dual-action mechanical and chemical protection. According to Bausch + Lomb, TotalVisc is the only dual pack in the United States that includes a dispersive and cohesive OVD formulated with sorbitol.

Free radicals form as a result of chemical reactions caused during various steps of cataract surgery, including phacoemulsification, irrigation/aspiration, and as part of the insertion and removal of instruments and implants. Free radicals can contribute to corneal damage and possible decompensation, which can lead to post-surgical complications such as a cloudy cornea.

In addition to providing increased free radical protection, StableVisc leads the cohesive OVD segment in fill volume at 1 milliliter, which reduces the need to open a second pack mid-procedure, thus contributing to surgical efficiency, according to Bausch + Lomb. TotalVisc also leads the dual pack OVD segment in fill volume of device with 1 milliliter of both ClearVisc and StableVisc.